Latest News

The authors of a review of 16 gene therapy trials for inherited retinal diseases explain why the pediatric evidence base remains thin and argue that individual-level, age-stratified reporting is the change most needed before CRISPR-based editing reaches children.

Majda Hadziahmetovic, MD, on MacTel neovascular warning signs, urgent referral, and how Encelto reshapes screening.

Mingo-Botín, MD, PhD, discusses ESCRS 2026 data on an EDOF IOL in post-LASIK eyes vs non-LASIK controls.

The 44th Congress of the ESCRS kicked off at ExCeL London with iNovation Day and the Opening Ceremony, setting the stage for a five-day programme.

Handheld IC1000 pairs rebound tonometry with camera-guided alignment

The FDA accepted Nanoscope's BLA for MOGENRY (sonpiretigene isteparvovec, MC-010), a gene therapy for retinitis pigmentosa with severe vision loss, supported by RESTORE trial data showing sustained BCVA improvement.

Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.

Dante Pieramici, MD, discusses the phase 3 COMO and CAPRI trials of EYP-1901 in diabetic macular edema and what 6-month dosing could mean for treatment burden.

Zero Blind Babies uses wide-field retinal imaging and telemedicine to expand ROP screening across Ghana, Ethiopia, Tanzania, and Syria—screening 400 infants weekly at $56 per QALY—while stressing that local staff and complete-pathway systems remain essential.

Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.

A priority review in Stargardt disease, two pivotal-trial milestones, an emerging bispecific for wet AMD, and new diagnostic guidance defined a busy August for retina.

Researchers from China and Singapore found that the macular microvasculature is altered as early as the pre-diabetic stage of the disease. The findings suggest that the status of the choriocapillaris can be used to monitor early metabolic disease.

Kodiak fully enrolled the first pivotal cohort of its phase 3 PEAK trial testing KSI-101 for inflammatory macular edema, with topline data expected December 2026.